Newly Merged dMed-Clinipace Turns Up Heat in China’s Booming CRO Market
Company’s new $50 million funding is the first since its April merger, as competition grows among nation’s contract research organizations (CROs) Key points: dMed-Clinipace’s raises $50 million in the…
RELATED ARTICLES
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Everest reaches new heights on growing drug sales
1952.HK
-
Cash-strapped Viva Biotech sells stake and plans spinoff
1873.HK
-
WuXi Biologics hatches new baby with ADC drug unit IPO
2269.HK
-
CStone breaks up with drugs partner as U.S. rollout stalls
2616.HK
- InSilico seeks IPO boost to get AI drugs over the line
Discover hidden China stock gems in our weekly newsletter